JP2011093881A - 月経前症候群の症状を緩和するための治療組成物及び方法 - Google Patents
月経前症候群の症状を緩和するための治療組成物及び方法 Download PDFInfo
- Publication number
- JP2011093881A JP2011093881A JP2010173298A JP2010173298A JP2011093881A JP 2011093881 A JP2011093881 A JP 2011093881A JP 2010173298 A JP2010173298 A JP 2010173298A JP 2010173298 A JP2010173298 A JP 2010173298A JP 2011093881 A JP2011093881 A JP 2011093881A
- Authority
- JP
- Japan
- Prior art keywords
- lecithin
- pms
- pharmaceutical
- phospholipase
- serine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 208000024891 symptom Diseases 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 31
- 206010036618 Premenstrual syndrome Diseases 0.000 title claims description 63
- 230000001225 therapeutic effect Effects 0.000 title 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 74
- 239000000787 lecithin Substances 0.000 claims abstract description 72
- 229940067606 lecithin Drugs 0.000 claims abstract description 72
- 235000010445 lecithin Nutrition 0.000 claims abstract description 72
- 229960001153 serine Drugs 0.000 claims abstract description 46
- 102000011420 Phospholipase D Human genes 0.000 claims abstract description 40
- 108090000553 Phospholipase D Proteins 0.000 claims abstract description 40
- 125000005313 fatty acid group Chemical group 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 235000013311 vegetables Nutrition 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 238000006911 enzymatic reaction Methods 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 5
- 235000015097 nutrients Nutrition 0.000 claims description 25
- 241000196324 Embryophyta Species 0.000 claims description 20
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 229940083466 soybean lecithin Drugs 0.000 claims description 11
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 235000013365 dairy product Nutrition 0.000 claims description 7
- 240000002791 Brassica napus Species 0.000 claims description 6
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 6
- 229940005741 sunflower lecithin Drugs 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 abstract description 4
- 239000008267 milk Substances 0.000 abstract description 4
- 210000004080 milk Anatomy 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 230000005906 menstruation Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000013404 behavioral symptom Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 206010006312 Breast swelling Diseases 0.000 description 2
- 206010006313 Breast tenderness Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000239366 Euphausiacea Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000004594 appetite change Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical group C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 108010092271 lacprodan PL-20 Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- -1 lysophospholipids Chemical class 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/606,975 US8399432B2 (en) | 2009-10-27 | 2009-10-27 | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014258058A Division JP5840284B2 (ja) | 2009-10-27 | 2014-12-19 | 月経前症候群（ｐｍｓ）に付随する症状の緩和剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011093881A true JP2011093881A (ja) | 2011-05-12 |
| JP2011093881A5 JP2011093881A5 (https=) | 2013-02-21 |
Family
ID=43610927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010173298A Withdrawn JP2011093881A (ja) | 2009-10-27 | 2010-08-02 | 月経前症候群の症状を緩和するための治療組成物及び方法 |
| JP2014258058A Active JP5840284B2 (ja) | 2009-10-27 | 2014-12-19 | 月経前症候群（ｐｍｓ）に付随する症状の緩和剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014258058A Active JP5840284B2 (ja) | 2009-10-27 | 2014-12-19 | 月経前症候群（ｐｍｓ）に付随する症状の緩和剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8399432B2 (https=) |
| EP (1) | EP2322184B1 (https=) |
| JP (2) | JP2011093881A (https=) |
| DK (1) | DK2322184T3 (https=) |
| ES (1) | ES2640009T3 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014162795A (ja) * | 2013-02-22 | 2014-09-08 | Lipogen Ltd | 月経前症候群に付随する症状及び月経前不快気分障害を緩和するのに使用される組成物 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018057737A1 (en) | 2016-09-22 | 2018-03-29 | Cash Alan B | Method to alleviate the symptoms of pms |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002029967A (ja) * | 2000-02-02 | 2002-01-29 | Nisshin Oil Mills Ltd:The | 月経前症候群症状緩和用食用油脂組成物 |
| JP2002302441A (ja) * | 2001-02-02 | 2002-10-18 | Nisshin Oil Mills Ltd:The | 月経前症候群症状緩和用組成物及び飲食物 |
| JP2003055216A (ja) * | 2001-08-03 | 2003-02-26 | Nisshin Oillio Ltd | 月経中症状緩和剤及びそれを含有する飲食物 |
| JP2003535029A (ja) * | 1999-08-31 | 2003-11-25 | イエナファルム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 良性ホルモン依存性婦人科疾患の治療及び予防のためのメソプロゲスチン（プロゲステロン受容体モジュレーター） |
| JP2005263668A (ja) * | 2004-03-17 | 2005-09-29 | Nof Corp | ホスファチジルセリン含有水性組成物及び用途 |
| WO2005091872A2 (en) * | 2004-03-04 | 2005-10-06 | Brierre Barbara T | Pharmaceutical composition and method for the transdermal delivery of magnesium |
| JP2006131572A (ja) * | 2004-11-08 | 2006-05-25 | Tomiyoshi Murakawa | 月経関連症状の緩和剤 |
| JP2006131571A (ja) * | 2004-11-08 | 2006-05-25 | Nakai Kosan:Kk | 月経関連症状の緩和剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3791951B2 (ja) | 1995-11-08 | 2006-06-28 | 株式会社ヤクルト本社 | 多価不飽和脂肪酸含有ホスファチジルセリンを含む油脂組成物の製造方法 |
| US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
| NZ591627A (en) | 2001-12-05 | 2012-09-28 | Teva Womens Health Inc | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| US6939877B2 (en) | 2002-09-12 | 2005-09-06 | Wyeth | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans |
| IL158139A0 (en) * | 2003-09-25 | 2004-09-27 | Enzymotec Ltd | Stabilized formulations of phosphatidyl serine |
| WO2005044176A2 (en) * | 2003-11-10 | 2005-05-19 | Lipogen Ltd. | Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same |
| US8846338B2 (en) * | 2008-08-07 | 2014-09-30 | Lipogen Ltd. | Processes for the preparation of phosphatides |
-
2009
- 2009-10-27 US US12/606,975 patent/US8399432B2/en active Active
-
2010
- 2010-02-24 EP EP10154498.9A patent/EP2322184B1/en active Active
- 2010-02-24 DK DK10154498.9T patent/DK2322184T3/en active
- 2010-02-24 ES ES10154498.9T patent/ES2640009T3/es active Active
- 2010-08-02 JP JP2010173298A patent/JP2011093881A/ja not_active Withdrawn
-
2014
- 2014-12-19 JP JP2014258058A patent/JP5840284B2/ja active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003535029A (ja) * | 1999-08-31 | 2003-11-25 | イエナファルム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 良性ホルモン依存性婦人科疾患の治療及び予防のためのメソプロゲスチン（プロゲステロン受容体モジュレーター） |
| JP2002029967A (ja) * | 2000-02-02 | 2002-01-29 | Nisshin Oil Mills Ltd:The | 月経前症候群症状緩和用食用油脂組成物 |
| JP2002302441A (ja) * | 2001-02-02 | 2002-10-18 | Nisshin Oil Mills Ltd:The | 月経前症候群症状緩和用組成物及び飲食物 |
| JP2003055216A (ja) * | 2001-08-03 | 2003-02-26 | Nisshin Oillio Ltd | 月経中症状緩和剤及びそれを含有する飲食物 |
| WO2005091872A2 (en) * | 2004-03-04 | 2005-10-06 | Brierre Barbara T | Pharmaceutical composition and method for the transdermal delivery of magnesium |
| JP2005263668A (ja) * | 2004-03-17 | 2005-09-29 | Nof Corp | ホスファチジルセリン含有水性組成物及び用途 |
| JP2006131572A (ja) * | 2004-11-08 | 2006-05-25 | Tomiyoshi Murakawa | 月経関連症状の緩和剤 |
| JP2006131571A (ja) * | 2004-11-08 | 2006-05-25 | Nakai Kosan:Kk | 月経関連症状の緩和剤 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014162795A (ja) * | 2013-02-22 | 2014-09-08 | Lipogen Ltd | 月経前症候群に付随する症状及び月経前不快気分障害を緩和するのに使用される組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8399432B2 (en) | 2013-03-19 |
| US20110098249A1 (en) | 2011-04-28 |
| JP5840284B2 (ja) | 2016-01-06 |
| JP2015057441A (ja) | 2015-03-26 |
| ES2640009T3 (es) | 2017-10-31 |
| EP2322184A1 (en) | 2011-05-18 |
| EP2322184B1 (en) | 2017-06-21 |
| DK2322184T3 (en) | 2017-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103200827B (zh) | 用于保持健康、以及治疗急性和慢性疾病的脂类补充剂 | |
| JP6016363B2 (ja) | 脳神経細胞新生剤 | |
| CA2352528C (en) | Phosphatidyl-l-serine and phosphatidic acid composition as anti-depressant, stress suppressor and mood improver | |
| JP2021502327A (ja) | オレウロペインの生物変換 | |
| CN107001980A (zh) | 醚磷脂及其制备方法 | |
| JPWO2008140026A1 (ja) | 新規のロイコトリエン受容体アンタゴニスト | |
| ES2861023T3 (es) | Composición reductora de grasa en la sangre y aplicación de la misma | |
| JP2016210696A (ja) | 学習記憶能力増強剤 | |
| JP5840284B2 (ja) | 月経前症候群（ｐｍｓ）に付随する症状の緩和剤 | |
| KR20140108281A (ko) | 건강 유지 및 급성 및 만성 장애의 치료를 위한 지질 보조제를 함유하는 츄어블 웨이퍼 | |
| JP5094094B2 (ja) | 食後血中インスリン上昇抑制剤 | |
| JP2009173556A (ja) | プロスタグランジンｅ２受容体、ｅｐ４アゴニストおよびそれを含有する組成物 | |
| US9248137B2 (en) | Compositions and methods for alleviating symptoms associated with perimenopausal and/or menopausal disorder or discomfort | |
| JP2008074794A (ja) | 肥満予防又は改善剤 | |
| JP6842093B2 (ja) | 学習記憶能力増強剤 | |
| CN108936626A (zh) | 针对肿瘤患者食用的生酮饮食组合物及其制备方法 | |
| EP3544630B1 (en) | Nutritional composition with resistant starch useful in the treatment of neoplastic diseases | |
| TW201625236A (zh) | 抗過敏劑、過敏性腹瀉的改善劑及醫藥組合物 | |
| JP2017165785A (ja) | 学習記憶能力増強剤 | |
| JP2004285006A (ja) | 抗アレルギー剤 | |
| JP2008074793A (ja) | ＰＰＡＲγ発現抑制剤 | |
| JP2011016843A (ja) | 歯周炎を治療又は予防するための組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130107 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140127 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140917 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141113 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141118 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20141208 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20141226 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150113 |